Empasiprubart

Empasiprubart (ARGX-117) a humanized inhibitory monoclonal antibody against complement C2. Empasiprubart prevents the formation of the C3 proconvertase and inhibits classical and lectin pathway activation upstream of C3 activation through binding to the Sushi-2 domain of C2. Empasiprubart exhibits pH- and calcium-dependent target binding. Empasiprubart prevents complement-mediated cytotoxicity in in vitro models for autoimmune hemolytic anemia and antibody-mediated rejection of organ transplants[1].

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[1]. Inge Van de Walle, et al.  ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol. 2021 Apr;147(4):1420-1429.e7.